Skip to Content

Etidronate Disease Interactions

There are 3 disease interactions with etidronate:


Etidronate (Includes Etidronate) ↔ Osteomalacia

Severe Potential Hazard, High plausibility

Applies to: Vitamin D Deficiency

The use of etidronate (for the treatment of Paget's disease or the treatment/prevention of heterotopic ossification) is contraindicated in patients with clinically overt osteomalacia. Etidronate can inhibit bone mineralization, which has resulted in osteomalacia and bone fractures in some patients. Accumulation of unmineralized osteoid is usually noticeable during prolonged, continuous use of high dosages (10 to 20 mg/kg/day) but may occur at lower dosages when use exceeds 6 months. The newer bisphosphonates (e.g., alendronate, pamidronate, risedronate, and tiludronate) do not cause mineralization defects and may be more appropriate for patients with osteomalacia, although clinical data may be lacking for the treatment of some conditions for which etidronate is used.


  1. "Product Information. Didronel I.V. Infusion (etidronate)." MGI Pharma Inc, Minnetonka, MN.
  2. Mautalen C, Gonzalez D, Blumenfeld EL, Santini Araujo E, Schajowicz F "Spontaneous fractures of uninvolved bones in patients with Paget's disease during unduly prolonged treatment with disodium etidronate (EHDP)." Clin Orthop Jun (1986): 150-5
  3. Evans RA, Dunstan CR, Hills E, Wong SY "Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget's disease of bone." Aust N Z J Med 13 (1983): 277-9
  4. Boyce BF, Smith L, Fogelman I, Johnston E, Ralston S, Boyle IT "Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease." Lancet 1 (1984): 821-4
  5. "Product Information. Didronel Tablets (etidronate)." Procter and Gamble Pharmaceuticals, Cincinnati, OH.
View all 5 references

Etidronate (Includes Etidronate) ↔ Upper Gastrointestinal Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Esophageal Disease, Peptic Ulcer, Gastroesophageal Reflux Disease

Etidronate administered orally may cause local irritation of the upper gastrointestinal mucosa. Its use is contraindicated in patients with esophageal abnormalities that delay esophageal emptying such as achalasia or strictures. Etidronate should be used with caution in patients with active upper gastrointestinal problems, such as Barrett's esophagus, dysphagia, gastritis, duodenitis, ulcers, etc, as cases of erosions, bleeding and perforation have been reported. Patients should be instructed to discontinue treatment immediately and seek medical attention if they develop dysphagia, retrosternal pain, or new or worsening heartburn.


Etidronate (Includes Etidronate) ↔ Renal Dysfunction

Moderate Potential Hazard, High plausibility

Applies to: Renal Dysfunction

Etidronate is eliminated intact by the kidney. There is no experience to specifically make recommendations in patients with impaired renal function. Etidronate dosage should be reduced when reductions in glomerular filtration rates are present. Patients with renal impairment should be closely monitored.


  1. "Product Information. Didronel Tablets (etidronate)." Procter and Gamble Pharmaceuticals, Cincinnati, OH.
  2. "Product Information. Didronel I.V. Infusion (etidronate)." MGI Pharma Inc, Minnetonka, MN.

etidronate drug Interactions

There are 283 drug interactions with etidronate

etidronate alcohol/food Interactions

There are 2 alcohol/food interactions with etidronate

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.